Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Gains from Investment Securities (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Gains from Investment Securities for 10 consecutive years, with $118665.0 as the latest value for Q2 2025.

  • On a quarterly basis, Gains from Investment Securities rose 556.4% to $118665.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $118665.0, a 203.19% increase, with the full-year FY2024 number at $827458.0, changed 0.0% from a year prior.
  • Gains from Investment Securities was $118665.0 for Q2 2025 at Harvard Bioscience, down from $827458.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $1.4 million in Q4 2021 to a low of -$168000.0 in Q4 2023.
  • A 5-year average of $384133.9 and a median of $118665.0 in 2025 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: surged 23313.6% in 2021, then plummeted 113.56% in 2023.
  • Harvard Bioscience's Gains from Investment Securities stood at $1.4 million in 2021, then fell by 11.82% to $1.2 million in 2022, then tumbled by 113.56% to -$168000.0 in 2023, then skyrocketed by 592.53% to $827458.0 in 2024, then plummeted by 85.66% to $118665.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Gains from Investment Securities are $118665.0 (Q2 2025), $827458.0 (Q4 2024), and $781958.0 (Q3 2024).